Bharat Biotech receives DCGI approval for Phase 3 clinical trials of its Intra-Nasal vaccine https://ift.tt/eA8V8J

Intra nasal vaccines are easier to administer in mass immunization campaigns and can also help in stopping the transmission of the virus. The trials for 0.5 ml single dose of nasal vaccine will be conducted at nine locations in the country.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3g7cGmm
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Labels

Blog Archive

Recent Posts

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.